The Accelerated Access Review (AAR) is being undertaken by the Department for Life Sciences, with the aim of speeding up access to innovative drugs, devices and diagnostics for NHS patients. The team at the AAR plan to release an interim report in October and have been taking submissions from stakeholders to inform this report.
Over the last month we have been engaging with our members around the Review, by creating a series of videos to inform on issues we would like to see addressed.
In our response to the Review we have raised some important points around patient data, engagement of patients, value based assessments and the value of innovative products. The most important point we would like to be considered is one around the process by which new medicinal products or medical technologies are placed on one of eight routes to patient access. This process needs to be made clear and transparent for patients.